A
Andrew Wood
Researcher at Children's Hospital of Philadelphia
Publications - 8
Citations - 1733
Andrew Wood is an academic researcher from Children's Hospital of Philadelphia. The author has contributed to research in topics: Neuroblastoma & Anaplastic lymphoma kinase. The author has an hindex of 5, co-authored 8 publications receiving 1509 citations. Previous affiliations of Andrew Wood include University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
The genetic landscape of high-risk neuroblastoma
Trevor J. Pugh,Olena Morozova,Edward F. Attiyeh,Edward F. Attiyeh,Shahab Asgharzadeh,Shahab Asgharzadeh,Jun S. Wei,Daniel Auclair,Scott L. Carter,Kristian Cibulskis,Megan Hanna,Megan Hanna,Adam Kiezun,Jaegil Kim,Michael S. Lawrence,Lee Lichenstein,Aaron McKenna,Chandra Sekhar Pedamallu,Chandra Sekhar Pedamallu,Alex H. Ramos,Alex H. Ramos,Erica Shefler,Andrey Sivachenko,Carrie Sougnez,Chip Stewart,Adrian Ally,Inanc Birol,Readman Chiu,Richard Corbett,Martin Hirst,Shaun D. Jackman,Baljit Kamoh,Alireza Hadj Khodabakshi,Martin Krzywinski,Allan Lo,Richard A. Moore,Karen Mungall,Jenny Q. Qian,Angela Tam,Nina Thiessen,Yongjun Zhao,Kristina A. Cole,Kristina A. Cole,Maura Diamond,Maura Diamond,Sharon J. Diskin,Sharon J. Diskin,Yael P. Mosse,Yael P. Mosse,Andrew Wood,Andrew Wood,Lingyun Ji,Lingyun Ji,Richard Sposto,Richard Sposto,Thomas C. Badgett,Wendy B. London,Yvonne Moyer,Yvonne Moyer,Julie M. Gastier-Foster,Julie M. Gastier-Foster,Malcolm A. Smith,Jaime M. Guidry Auvil,Daniela S. Gerhard,Michael D. Hogarty,Michael D. Hogarty,Steven J.M. Jones,Eric S. Lander,Stacey Gabriel,Gad Getz,Robert C. Seeger,Robert C. Seeger,Javed Khan,Marco A. Marra,Matthew Meyerson,Matthew Meyerson,John M. Maris +76 more
TL;DR: The authors reported a low median exonic mutation frequency of 0.60 per Mb (0.48 nonsilent) and notably few recurrently mutated genes in high-risk neuroblastoma.
Journal ArticleDOI
Copy number variation at 1q21.1 associated with neuroblastoma
Sharon J. Diskin,Cuiping Hou,Joseph T. Glessner,Edward F. Attiyeh,Edward F. Attiyeh,Marci Laudenslager,Kristopher R. Bosse,Kristina A. Cole,Yael P. Mosse,Yael P. Mosse,Andrew Wood,Jill E. Lynch,Katlyn Pecor,Maura Diamond,Cynthia Winter,Kai Wang,Cecilia Kim,Elizabeth A. Geiger,Patrick McGrady,Alexandra I. F. Blakemore,Wendy B. London,Tamim H. Shaikh,Tamim H. Shaikh,Jonathan P. Bradfield,Struan F.A. Grant,Struan F.A. Grant,Hongzhe Li,Marcella Devoto,E. Rappaport,E. Rappaport,Hakon Hakonarson,Hakon Hakonarson,John M. Maris,John M. Maris +33 more
TL;DR: The identification of a common CNV at chromosome 1q21.1 associated with neuroblastoma in the discovery set is described and a previously unknown transcript within the CNV that showed high sequence similarity to several neuro Blastoma breakpoint family genes and represents a new member of this gene family (NBPF23).
Journal ArticleDOI
ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma
Scott C. Bresler,Daniel A. Weiser,Daniel A. Weiser,Peter J. Huwe,Jin H. Park,Kateryna Krytska,Hannah T. Ryles,Marci Laudenslager,Eric F. Rappaport,Andrew Wood,Patrick McGrady,Michael D. Hogarty,Michael D. Hogarty,Wendy B. London,Wendy B. London,Ravi Radhakrishnan,Mark A. Lemmon,Yael P. Mosse,Yael P. Mosse +18 more
TL;DR: These studies identify ALK genomic status as a clinically important therapeutic stratification tool in neuroblastoma and will allow tailoring of ALK-targeted therapy to specific mutations, and identify oncogenic (constitutively activating) from nononcogenic mutations.
Journal ArticleDOI
Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma
Lori S. Hart,JulieAnn Rader,Pichai Raman,Vandana Batra,Mike R. Russell,Matthew Tsang,Maria Gagliardi,Lucy Chen,Daniel Martinez,Yimei Li,Yimei Li,Andrew Wood,Sunkyu Kim,Sudha Parasuraman,Scott Delach,Kristina A. Cole,Kristina A. Cole,Shiva Krupa,Markus Boehm,Malte Peters,Giordano Caponigro,John M. Maris,John M. Maris +22 more
TL;DR: Combined binimetinib and ribociclib treatment shows therapeutic synergy across a broad panel of high-risk neuroblastoma preclinical models, and these data support testing this combination therapy in relapsed high- risk neuroblastomas patients, with focus on cases with hyperactivated RAS–MAPK signaling.
Journal ArticleDOI
Antibody targeting of anaplastic lymphoma kinase induces cytotoxicity of human neuroblastoma
Erica L. Carpenter,E. A. Haglund,Emily M. Mace,D. Deng,Daniel Martinez,Andrew Wood,Adrian K. Chow,Daniel A. Weiser,Lili T. Belcastro,Cynthia Winter,Scott C. Bresler,Shahab Asgharzadeh,Robert C. Seeger,Huaqing Zhao,Rong Guo,James G. Christensen,Jordan S. Orange,Bruce R. Pawel,Mark A. Lemmon,Yael P. Mosse,Yael P. Mosse +20 more
TL;DR: It is shown here that an antagonistic ALK antibody inhibits cell growth and induces in vitro antibody-dependent cellular cytotoxicity of human neuroblastoma-derived cell lines, supporting the concept of ALK-targeted immunotherapy as a highly promising therapeutic strategy for neuroblastomas with mutated or wild-type ALK.